InvestingDaily.com

Account Information

  • My Account

    Manage all your subscriptions, update your address, email preferences and change your password.

  • Help Center

    Get answers to common service questions, ask the analyst or contact our customer service department.

  • My Stock Talk Profile

    Update your stock talk name and/or picture.



Close
FEATURED STRATEGY

$1,230 in Instant Income?

$1,230 in Instant Income?Our top income expert recently pulled the wraps off his breakthrough moneymaking technique. And he proved beyond a shadow of a doubt how you can use it to generate instant cash payouts of up to $1,230 (or more). Over and over again. But then he took things a big step further and guaranteed you can make $1 million by following his program. And the second he did, our phones went nuts! Space is limited — get the details here.

 

 

A “Dividend Aristocrat” to Beat the Generic Drug Bloodbath

By John Persinos on August 8, 2017

Short sellers of generic biotech stocks are wreaking more havoc than a tornado in a trailer park. Global generic drug makers have been getting pounded over the past week, a sell-off triggered in large part by horrific second-quarter results from industry bellwether Teva Pharmaceutical Industries (NYSE: TEVA).

However, remember this timeless contrarian advice: one investor’s bloodbath is another’s buffet. Below, I pinpoint a generic pharmaceutical play that’s not only weathering the storm but also positioned to soar when the generic drug business inevitably bounces back. First, let’s breakdown the continuing slaughter in this sector — its reasons, extent and aftermath.

Falling prices for generic drugs, although a benefit for consumers, have been weighing on drug companies of all types. The U.S. Food and Drug Administration has been speeding-up its approval of generic drugs while at the same time the industry has been consolidating to achieve economies of scale and cost efficiencies.

But there’s an unexpected twist to this story. Major pharmaceutical companies have started squeezing profits from more expensive brand-name drugs by pressuring the retail supply chain to favor them over generics. Through rebates and other incentives, Big Pharma is getting drugstores and health care providers to increasingly prescribe brand name drugs over generics, giving consumers little choice but to pay more. This Alice-in-Wonderland pricing environment has caught generic drug makers in a double bind.

The upshot has been severe generic drug price erosion. Fueling price pressure is the Affordable Care Act, aka Obamacare, which enforces strict cost control measures on health services and drugs. Last month’s demise of Trumpcare only solidifies this trend, because it leaves Obamacare and its cost-containment provisions in place.

The Teva Apocalypse

Leading the industry’s devastation has been Teva Pharmaceutical Industries, the largest generic drug maker in the world. Based in Israel and with operations around the world, Teva is renowned for its leading-edge drug research and a portfolio of quality products. But industry headwinds have been too much for Teva.

As a whole, second-quarter corporate earnings have been robust. Teva, though, fell flat on its face. The company last Thursday reported second-quarter earnings per share (EPS) of 99 cents, which missed the consensus EPS estimate of $1.06 by 6.6%. EPS in the same period a year ago was $1.22.

Teva’s revenue of $5.6 billion missed consensus expectations of $5.85 billion by 2.8%. In response to the plunge in earnings as well as its shrinking cash flow, the beleaguered company cut its dividend and slashed earnings and revenue guidance for full-year 2017.

Wall Street’s reaction was swift and brutal. The stock got pounded on Thursday, Friday and Monday, losing more than a third of its value. Teva stock is now down 48.7% year to date, hitting its lowest levels since 2003. Ouch.

It doesn’t help that Teva has been on the hunt for a new CEO ever since current honcho Erez Vigodman said in February that he would step down.

I actually think Teva possesses several inherent strengths, including a powerful and proven R&D capability, that will come to the fore over the long haul. But until the company finds a new CEO to right the ship, stay away from the stock. It’s not a value play; right now it’s a value trap.

Teva’s miserable earnings report underscored widespread troubles in the generic drug business and dragged down the company’s main rivals as well. Also taking it on the chin since Thursday have been Perrigo (NYSE: PRGO), Dr. Reddy’s Laboratories (NYSE: RDY)Endo International (NSDQ: ENDP), Mylan (NSDQ: MYL), and Taro Pharmaceutical (NYSE: TARO).

The VanEck Vectors Generic Drugs ETF (NSDQ: GNRX) dropped 4.1% on Thursday and year to date has generated a total return of only 4.9%, compared to 11.4% for the S&P 500.

Companies focused on generics have taken the worst beating over the past week, while Big Pharma stocks with brand name blockbusters have held up relatively well. Indeed, the iShares Nasdaq Biotechnology ETF (NSDQ: IBB) has generated a total return of 20.4% year to date.

A shrewd strategy now is to pick a blue-chip drug maker with a foot in both the generic and branded worlds, with diverse activities in the health sector. The generic drug business isn’t going away and its eventual turnaround will provide a profit catalyst for the best stocks to breakout.

A Survivor in Aristocratic Clothing

All of which brings me to Chicago-based Abbott Laboratories (NYSE: ABT), a drug maker that’s on the list of “Dividend Aristocrats.” Abbott can survive the sustained pressure on generic drug prices but also boasts sufficient product diversity to withstand future turbulence in the broader stock market.

To earn the honored title of Dividend Aristocrat, a company must typically have raised dividends for at least 25 years. More precisely, the company must have a dividend policy that increased its dividend every year for those 25 years.

Abbott consistently makes S&P’s list of Dividend Aristocrats and 2017 was no exception. Keep in mind, a proven hedge against looming stock market corrections is to increase your portfolio’s weighting toward proven dividend-paying stocks.

If the broader indices tumble this year as I expect, the best dividend-paying stocks should generate less volatility and provide a cushion for risk-averse investors.

Well-established companies such as Abbott that dole out regular dividends tend to outperform the overall market over both the short and long haul. Since 1927, dividend-paying stocks have returned 11% per year versus 8% for non-dividend paying stocks. In June, Abbott declared its 374th consecutive quarterly dividend to be paid since 1924.

With a market cap of $85.4 billion, Abbott serves customers in more than 150 countries and employs approximately 70,000 people. The company operates internationally across four business segments: Branded Generics, Medical Devices, Diagnostics and Nutrition. These businesses provide a diversified customer base and payer mix.

The company’s drug portfolio includes Humira, for rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and psoriasis; Norvir, for HIV; Depakote, an anticonvulsant; and Synthroid, a synthetic thyroid hormone.

Abbott also offers a wide range of medical devices and diagnostic tests used worldwide by doctor’s offices, hospitals, laboratories, and blood banks to diagnose, monitor and treat diseases such as cancer, HIV, hepatitis, heart failure and metabolic disorders.

Abbott reported second-quarter worldwide sales of $6.6 billion, a year-over-year increase of 24.4%. EPS came in at 62 cents, exceeding the previous guidance range of 59 cents to 61 cents. Management raised its full-year 2017 EPS guidance range, reflecting expectations of double-digit growth.

The average analyst expectation is that ABT’s year-over-year earnings growth will reach 10.2% in the current quarter, 12.3% next quarter, 13.2% in the current year, and 11.6% next year. My own calculations show that ABT’s five-year earnings growth should reach at least 11% on an annualized basis.

The annual yield on ABT’s dividend is 2.15%. Abbott’s stock is now poised for outsized growth, as it taps into some of the health sector’s biggest opportunities and leapfrogs the woes currently bedeviling the generic drug sector. Year to date, ABT shares are up 28.3%, with further upside in the cards.

 


You might also enjoy…

 

R.I.P Bull Market—Here’s How To Protect Your Wealth

I hope you’ve enjoyed the phenomenal bull market of the past eight years…

Because it’s about to come to a screeching halt.

The Federal Reserve’s nearly decade-long spending spree has finally come to an end.

With no other options left at their disposal, the Fed has no other choice than to raise interest rates to keep inflation in check.

And that leaves you with two options…

Do nothing and suffer the agony of watching the profits you’ve accumulated over the years evaporate right before your eyes…

Or reposition your portfolio and invest in companies which prosper as inflation rises and interest rates soar.

I think the choice is clear. And I’ll show you the best new positions you can take if you click here.

Stock Talk — Post a comment Comment Guidelines

Our Stock Talk section is reserved for productive dialogue pertaining to the content and portfolio recommendations of this service. We reserve the right to remove any comments we feel do not benefit other readers. If you have a general investment comment not related to this article, please post to our Stock Talk page. If you have a personal question about your subscription or need technical help, please contact our customer service team. And if you have any success stories to share with our analysts, they’re always happy to hear them. Note that we may use your kind words in our promotional materials. Thank you.

You must be logged in to post to Stock Talk OR create an account.

Create a new Investing Daily account

  • - OR -

* Investing Daily will use any information you provide in a manner consistent with our Privacy Policy. Your email address is used for account verification and will remain private.